20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Tyra Biosciences Inc (TYRA) operates in the BIOTECHNOLOGY industry and is headquartered in Carlsbad, United States with about 87 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, TYRA reported $0M in revenue and ($120M) in net income.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($1M) | ($1M) | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($160M) | ($133M) | ($104M) | ($80M) | ($59M) | ($26M) | ($9M) | ($3M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($149M) | ($120M) | ($86M) | ($69M) | ($52M) | ($26M) | ($9M) | ($4M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($148M) | ($119M) | ($86M) | ($69M) | ($59M) | ($26M) | ($9M) | ($3M) |
| Earnings Per Share (EPS) | $-2.40 | $-2.01 | $-1.51 | $-1.62 | $-1.23 | $-0.63 | $-0.22 | $-0.10 |
| Shares Outstanding (M) | 66M | 60M | 57M | 43M | 42M | 41M | 43M | 43M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | — | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($49M) | ($42M) | ($37M) | ($33M) | ($31M) | ($32M) | ($30M) | ($29M) |
| Operating Margin % | — | — | — | — | — | — | -5996.8% | — |
| Net Income | ($46M) | ($39M) | ($34M) | ($30M) | ($28M) | ($28M) | ($26M) | ($24M) |
| Net Margin % | — | — | — | — | — | — | -5155.4% | — |
| EBITDA | ($45M) | ($39M) | ($34M) | ($30M) | ($28M) | ($28M) | ($25M) | ($24M) |
| Earnings Per Share (EPS) | $-0.69 | $-0.64 | $-0.57 | $-0.50 | $-0.47 | $-0.47 | $-0.43 | $-0.41 |
| Shares Outstanding (M) | 66M | 62M | 60M | 60M | 60M | 59M | 59M | 59M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($110M) | ($95M) | ($70M) | ($50M) | ($50M) | ($24M) | ($8M) | ($3M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $1M | $1M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($110M) | ($95M) | ($70M) | ($51M) | ($51M) | ($24M) | ($8M) | ($3M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($31M) | ($33M) | ($24M) | ($22M) | ($24M) | ($25M) | ($20M) | ($18M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($31M) | ($33M) | ($24M) | ($22M) | ($24M) | ($25M) | ($20M) | ($18M) |
| FCF Margin % | — | — | — | — | — | — | -3950.8% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $383M | $283M | $364M | $226M | $266M | $307M | $16M | $1M |
| Cash & Cash Equivalents | $74M | $77M | $92M | $58M | $251M | $302M | $15M | $0M |
| Total Liabilities | $30M | $23M | $20M | $22M | $8M | $5M | $30M | $5M |
| Total Debt (Short + Long-Term) | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $354M | $259M | $343M | $204M | $258M | $302M | ($14M) | ($5M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TYRA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms